Search

everythinglearnresearchcommunity

for

Search:↓

Antiandrogen drugs can reduce PSA levels in women with excess hair, suggesting PSA is a sign of male hormone activity in women.

Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.

Finasteride lowers PSA levels about the same whether taken at 1 mg or 5 mg daily.

Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.

Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.

Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.

Vertex baldness has higher DHT levels than frontal baldness, but testosterone and PSA levels are similar.

Women with PCOS have higher PSA levels, which are linked to increased male hormone levels and hirsutism.

Men with less sun-sensitive skin have lower PSA levels, while men with more sun-sensitive skin have higher PSA levels.

Taking 1mg of finasteride daily for hair loss can lower PSA levels by 40-50%, so to keep PSA effective as a cancer screening tool, the PSA value should be doubled during treatment.

Finasteride reduces prostate size and PSA levels in young patients.

Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.

PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.

Finasteride for hair loss lowers PSA levels, so PSA values need adjusting when screening for prostate cancer.

Women with androgenetic alopecia (hair loss) have normal prostate specific antigen levels but higher testosterone levels.

Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.

Dutasteride reduces DHT more effectively than finasteride.

No link found between hair loss severity and PSA levels in men.

Finasteride significantly reduces PSA levels in men, and doctors should adjust PSA readings for those taking the drug.

No link between hair loss severity and PSA levels in men.

Low-dose finasteride and dutasteride reduce PSA levels by 27.8% in men with male androgenetic alopecia.

Low dose finasteride causes only small changes in PSA levels in older men with BPH.

Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.

PSA could be a marker for hyperandrogenism in women, but more research is needed.

CT scans can find serious prostate cancer even when PSA levels are low.

Finasteride lowers PSA levels in men, certain factors increase testicular cancer risk, and current guidelines for penile cancer may lead to unnecessary surgeries.

Finasteride reduces prostate size and serum levels, helping manage benign prostatic hyperplasia, without affecting prostate cancer detection. Regular monitoring is needed for users.

Finasteride doesn't harm male fertility or sperm quality, but may slightly reduce ejaculate volume.